Lou Tartaglia, PhD

Venture Partner

Lou Tartaglia, Ph.D. joined 5AM Ventures in January 2016 as an Executive-in-Residence and Chief Executive Officer of 4:59 Therapeutics, a company seeded for identifying and acquiring innovative assets, and has recently transitioned into a Venture Partner role. Dr. Tartaglia has over 25 years of scientific and therapeutic product project leadership in the biotech industry. Prior to joining 5AM, Dr. Tartaglia served as a Partner at Third Rock Ventures where he played an integral role in the overall scientific diligence, formation and development of its portfolio companies. He has also served as Chief Executive Officer of Solstice Biologics and General Manager at GeneLogic. Before that, he was Vice President of Metabolic Diseases at Millennium Pharmaceuticals where he was responsible for the discovery and development of multiple therapeutic programs. Earlier in his career, Dr. Tartaglia did his postdoctoral work at Genentech in the laboratory of Dr. David Goeddel. He completed his Ph.D. in biochemistry at the University of California, Berkeley in the laboratory of Dr. Bruce Ames and his B.S. in chemistry at the State University of New York at Albany.  Dr. Tartaglia is based in the Boston, MA office.